Targeting IL-1β or IL-1Ra could represent an effective therapeutic strategy for addressing the inflammatory processes in ischemic stroke, both during the acute phase and as part of the chronic conditions that contribute to atherosclerosis and increase the risk of stroke [44]. The gene discussed is IL1B; the disease is ischemic stroke.